Zomedica Showcases Success in Treating Canine Fibrotic Myopathy with PulseVet(R) Shock Wave Therapy

ANN ARBOR, MI - Zomedica Corp. (NYSE American:ZOM), a key player in the veterinary health sector, has recently shared insights on the efficacy of PulseVet electro-hydraulic shock wave therapy in treating fibrotic myopathy in working dogs. This condition, often seen in breeds like German Shepherd Dogs used in Military and Police force, has found a promising treatment avenue that allows affected dogs to extend their working lives by an average of 32 months post-diagnosis.

The supporting case series, led by Drs. Frank Tsai, Leilani Alvarez, and their team at Schwarzman Animal Medical Center, New York, is published in Frontiers in Veterinary Science. The study exemplifies the therapy’s role in not only fibrotic myopathy but also in treating various conditions in canines and equines, highlighting its versatility in animal healthcare.

Dr. Alvarez expressed how fibrotic myopathy, typically a career-ender, can now be approached with a solution that significantly prolongs the working capabilities of these valuable animals. Adrian Lock from Zomedica and CEO Larry Heaton both acknowledged the profound impact and market expansion potential of PulseVet therapy in the veterinary sector.

With a commitment to advancing non-invasive, regenerative treatments, Zomedica's progress with PulseVet shock wave therapy underscores its dedication to improving veterinary care and expanding treatment possibilities for animal patients globally.